Novilytic secures two strategic patents for its Proteometer^® Platform

Novilytic, an innovator in molecular recognition technology, is proud to announce that the United States Patent and Trademark Office has granted two comprehensive new patents covering its Proteometer platform. The patents, titled “Molecular Recognition Assays of Critical Structure Attributes in Proteoforms,” and “Proteoform Specific Process Validation,” protect Novilytic’s proprietary approach across all existing and future Proteometer applications.

These new patents represent Novilytic’s most comprehensive intellectual property protection yet, further solidifying the company's leadership in molecular structure analysis and its ability to bring innovative products to market. They offer additional reassurance to customers, partners, and distributors that Novilytic’s technology is both unique and defensible.

From a technical perspective, the patents protect Novilytic's unique ability to analyse entire molecules, including monoclonal antibodies (mAbs), multi-specifics, antibody-drug conjugates (ADCs), and fusion proteins. They confirm that Novilytic is the only platform capable of determining whether these molecules retain their therapeutic potential. Additionally, they protect the use of Novilytic’s technologies across various analytical systems, including high-performance liquid chromatography (HPLC), fluorescence plate readers, and capillary electrophoresis.

“This is a chasm-crossing moment for us,” said Paul Dreier, CEO of Novilytic. “These patents not only strengthen our legal position but validate the novelty and essential role of our technology in pharmaceutical R&D (Discovery), clone selection, and Process R&D. Now more than ever, Novilytic is poised to accelerate the industry’s shift towards smarter, data-driven, more efficient medicine development.”

The patents are also recognised internationally, including in the European Union, United Kingdom, and Japan. These protections ensure coverage for the target market.

“The patents effectively protect us from competitive copycats, and to date, we’ve seen none,” said Eric Bowen, Director of Product Management. “Even though products like older style Protein A Affinity Columns attempt to achieve similar results, they cost nearly twice as much and lack the accuracy of our platform. They're truly not playing in the same sandbox.”

Novilytic’s Proteometer platform currently comprises three patented products. These tools enable upstream pharmaceutical development teams to eliminate sample preparation, cut costs, reduce time-to-market, and streamline analytical workflows. They plan to release at least two new versions of the Proteometer based on customer input over the next year.